Posted by Michael Wonder on 21 May 2021
TGA evaluating first monoclonal antibody treatment for COVID-19 sotrovimab - GlaxoSmithKline
21 May 2021 - The Therapeutic Goods Administration granted a provisional determination to GlaxoSmithKline in relation to the monoclonal antibody treatment sotrovimab (GSK4182136) on 14 April 2021.
The TGA has now received GSK's application for provisional registration and is evaluating the preliminary data for sotriovimab.
